Fasturtec TLS Treatment / Prophylysis
An open-label study to determine the efficacy and safety of Rasburicase used for the prevention and treatment of tumor lysis syndrome
Tumor Lysis Syndrome
DRUG: urate oxidase
To assess the uricolytic response to rasburicase treatment, 5 weeks (3 to 7 days of treatment, with follow-up of 4 weeks after the last study drug injection)
To evaluate tumor lysis risk factors, treatments for tumor lysis syndrome and complications of treatment in patients treated prophylactically or therapeutically for tumor lysis syndrome, 5 weeks (3 to 7 days of treatment, with follow-up of 4 weeks after the last study drug injection)
An open-label study to determine the efficacy and safety of Rasburicase used for the prevention and treatment of tumor lysis syndrome